MENU
+Compare
SGMO
Stock ticker: NASDAQ
AS OF
May 14, 04:59 PM (EDT)
Price
$0.44
Change
-$0.02 (-4.35%)
Capitalization
100.39M

SGMO stock forecast, quote, news & analysis

Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases... Show more

Industry: #Biotechnology
SGMO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
Ad is loading...
A.I.Advisor
a Summary for SGMO with price predictions
May 13, 2025

SGMO saw its Stochastic Oscillator leaves the overbought zone

The Stochastic Oscillator for SGMO moved out of overbought territory on May 13, 2025. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 52 similar instances where the indicator exited the overbought zone. In of the 52 cases the stock moved lower. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on May 13, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on SGMO as a result. In of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for SGMO turned negative on May 13, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SGMO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for SGMO entered a downward trend on April 16, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator entered the oversold zone -- be on the watch for SGMO's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where SGMO advanced for three days, in of 240 cases, the price rose further within the following month. The odds of a continued upward trend are .

SGMO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.409) is normal, around the industry mean (14.420). P/E Ratio (0.000) is within average values for comparable stocks, (65.047). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.146). Dividend Yield (0.000) settles around the average of (0.024) among similar stocks. P/S Ratio (1.528) is also within normal values, averaging (254.920).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. SGMO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SGMO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Exelixis (NASDAQ:EXEL), Incyte Corp (NASDAQ:INCY), Moderna (NASDAQ:MRNA), Sarepta Therapeutics (NASDAQ:SRPT), BioCryst Pharmaceuticals (NASDAQ:BCRX), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.14B. The market cap for tickers in the group ranges from 151 to 289.83B. NONOF holds the highest valuation in this group at 289.83B. The lowest valued company is MYMX at 151.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -0%. For the same Industry, the average monthly price growth was 5%, and the average quarterly price growth was -6%. CTMX experienced the highest price growth at 148%, while PLRZ experienced the biggest fall at -98%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 9%. For the same stocks of the Industry, the average monthly volume growth was 56% and the average quarterly volume growth was 107%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 85
Price Growth Rating: 62
SMR Rating: 90
Profit Risk Rating: 95
Seasonality Score: 15 (-100 ... +100)
View a ticker or compare two or three
SGMO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published General Information

General Information

a developer of transcription factors in the regulation of genes

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
501 Canal Boulevard
Phone
+1 510 970-6000
Employees
405
Web
https://www.sangamo.com